Rechallenging with Anthracyclines and Taxanes in Metastatic Breast Cancer

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2010 Sep 3

PMID 20808300

Citations 30

Authors

Carlo Palmieri

Jonathan Krell

Colin R James

Catherine Harper-Wynne

Vivek Misra

Susan Cleator

David Miles

Affiliations

Soon will be listed here.

Abstract

Adjuvant use of anthracycline-taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the question of how best to manage those patients who relapse following adjuvant therapy, and whether there is a role for rechallenging in the metastatic setting with the same agent, or class of agent, that has been utilized in the adjuvant setting. This Review examines the evidence for rechallenging with both anthracyclines and taxanes, and highlights the issues that need to be examined in the context of future clinical trials.

Citing Articles

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.

Guchelaar N, Mathijssen R, de Boer M, van Bekkum M, Heijns J, Vriens B EClinicalMedicine. 2025; 80:103065.

PMID: 40017682 PMC: 11867194. DOI: 10.1016/j.eclinm.2024.103065.

Interleukin 15-Presenting Nanovesicles with Doxorubicin-Loaded Ferritin Cores for Cancer Immunochemotherapy.

Zhai Y, Zhang W, Wang J, Kong Y, Rong R, Lang T Adv Sci (Weinh). 2024; 12(4):e2409194.

PMID: 39625860 PMC: 11789581. DOI: 10.1002/advs.202409194.

Efficacy and safety of rechallenge [Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).

Rosar F, Schuler J, Burgard C, Blickle A, Bartholoma M, Maus S Eur J Nucl Med Mol Imaging. 2024; 51(13):4151-4162.

PMID: 39008067 PMC: 11527919. DOI: 10.1007/s00259-024-06825-4.

Drug-tolerant persister cells in cancer: the cutting edges and future directions.

Pu Y, Li L, Peng H, Liu L, Heymann D, Robert C Nat Rev Clin Oncol. 2023; 20(11):799-813.

PMID: 37749382 DOI: 10.1038/s41571-023-00815-5.

Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-β, and MAPK signaling pathways during breast tumor progression.

Maharati A, Moghbeli M J Transl Med. 2023; 21(1):556.

PMID: 37596669 PMC: 10439650. DOI: 10.1186/s12967-023-04434-7.

References

Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6):976-83. DOI: 10.1200/JCO.2003.02.063. View

OShaughnessy J, Twelves C, Aapro M . Treatment for anthracycline-pretreated metastatic breast cancer. Oncologist. 2002; 7 Suppl 6:4-12. DOI: 10.1634/theoncologist.7-suppl_6-4. View

Fountzilas G, Kalofonos H, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P . Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2004; 15(10):1517-26. DOI: 10.1093/annonc/mdh395. View

Trudeau M, Clemons M, Provencher L, Panasci L, Yelle L, Rayson D . Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol. 2009; 27(35):5906-10. DOI: 10.1200/JCO.2009.22.7504. View

De Laurentiis M, Cancello G, DAgostino D, Giuliano M, Giordano A, Montagna E . Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008; 26(1):44-53. DOI: 10.1200/JCO.2007.11.3787. View

Luikart S, Witman G, Portlock C . Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma. Cancer. 1984; 54(7):1252-5. DOI: 10.1002/1097-0142(19841001)54:7<1252::aid-cncr2820540703>3.0.co;2-6. View

Catimel G, Chauvin F, Guastalla J, Rebattu P, Biron P, Clavel M . FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy. Ann Oncol. 1994; 5(1):95-7. DOI: 10.1093/oxfordjournals.annonc.a058707. View

Seidman A, Hochhauser D, Gollub M, Edelman B, Yao T, Hudis C . Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996; 14(6):1877-84. DOI: 10.1200/JCO.1996.14.6.1877. View

Blum J, Savin M, Edelman G, Pippen J, Robert N, Geister B . Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2008; 7(11):850-6. DOI: 10.3816/CBC.2007.n.049. View

10.

Gray R, Bhattacharya S, Bowden C, Miller K, Comis R . Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009; 27(30):4966-72. PMC: 2799052. DOI: 10.1200/JCO.2008.21.6630. View

11.

Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M . Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008; 100(2):121-33. DOI: 10.1093/jnci/djm287. View

12.

Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, OReilly S . Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009; 373(9676):1681-92. PMC: 2687939. DOI: 10.1016/S0140-6736(09)60740-6. View

13.

Sparano J, Makhson A, Semiglazov V, Tjulandin S, Balashova O, Bondarenko I . Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant.... J Clin Oncol. 2009; 27(27):4522-9. DOI: 10.1200/JCO.2008.20.5013. View

14.

Stoger H, Schmid M, Bauernhofer T, Moser R, Ploner F, Derstvenscheg E . A phase II trial of weekly high-dose folinic acid and 5-fluorouracil in combination with epirubicin as salvage chemotherapy in advanced breast cancer. Oncology. 1994; 51(6):518-22. DOI: 10.1159/000227397. View

15.

Buzdar A, Legha S, Hortobagyi G, Yap H, Wiseman C, Distefano A . Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer. 1981; 47(12):2798-802. DOI: 10.1002/1097-0142(19810615)47:12<2798::aid-cncr2820471207>3.0.co;2-t. View

16.

Miles D, Chan A, Dirix L, Cortes J, Pivot X, Tomczak P . Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28(20):3239-47. DOI: 10.1200/JCO.2008.21.6457. View

17.

Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M . Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol. 2009; 20(7):1210-5. DOI: 10.1093/annonc/mdn781. View

18.

Kardinal C, Perry M, Korzun A, Rice M, Ginsberg S, Wood W . Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081. Cancer. 1988; 61(3):415-9. DOI: 10.1002/1097-0142(19880201)61:3<415::aid-cncr2820610302>3.0.co;2-q. View

19.

Giotta F, Lorusso V, Maiello E, Filippelli G, Valerio M, Caruso M . Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol. 2007; 18 Suppl 6:vi66-9. DOI: 10.1093/annonc/mdm228. View

20.

Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D . Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005; 16(11):1762-71. DOI: 10.1093/annonc/mdi366. View